Evogene (EVGN) Receives Daily Coverage Optimism Rating of 0.13

News coverage about Evogene (NYSE:EVGN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evogene earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.4667280580715 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Evogene (NYSE:EVGN) traded down 0.86% during mid-day trading on Friday, reaching $4.63. 5,327 shares of the company’s stock traded hands. The company’s market cap is $119.20 million. The company’s 50 day moving average is $4.51 and its 200 day moving average is $4.95. Evogene has a 12-month low of $4.22 and a 12-month high of $6.40.

Evogene (NYSE:EVGN) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). The company had revenue of $1.18 million for the quarter. Evogene had a negative net margin of 235.47% and a negative return on equity of 18.60%. On average, analysts predict that Evogene will post ($0.71) EPS for the current fiscal year.

WARNING: This story was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://sportsperspectives.com/2017/10/13/evogene-evgn-receives-daily-coverage-optimism-rating-of-0-13.html.

Evogene Company Profile

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Insider Buying and Selling by Quarter for Evogene (NYSE:EVGN)

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply